Also, a phase 2 clinical trial with 122 participants testing intranasal oxytocin in FTD is ongoing, with assessing changes in neuropsychiatric inventory (NPI) apathy/indifference domain scores as the primary endpoint (110). The gene discussed is OXT; the disease is frontotemporal dementia.